EMPACT-MI Results: Empagliflozin After Acute Myocardial Infarction

Patients with acute myocardial infarction are at a high risk of heart failure and death. Despite advances in care and reduction in the rate of recurrent myocardial infarctions, the risk for heart failure continues to be unacceptably high. No intervention in 2 decades has been shown to improve this risk.   In this interview, Javed Butler, MD, MPH, MBA, and Sun Moon Kim, MD, FACC, discuss the results of the EMPACT-MI trial. 

Om Podcasten

The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.